Campbell D Flynn1, David H Tian2, Ashley Wilson-Smith2, Tirone David3, George Matalanis4, Martin Misfeld5, Stefano Mastrobuoni6, Gebrine El Khoury6, Tristan D Yan2,7,8. 1. Department of Cardiothoracic Surgery, Royal North Shore Hospital, St Leonards, Australia. 2. Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia. 3. Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital and University of Toronto, Toronto, ON, Canada. 4. Department of Cardiac Surgery, Austin Health, Melbourne, Australia. 5. Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. 6. Department of Cardiovascular and Thoracic Surgery, Saint Luc's Hospital, Brussels, Belgium. 7. University of Sydney, Royal Prince Alfred Hospital, Sydney, Australia. 8. University of Sydney, Sydney Adventist Hospital, Sydney, NSW, Australia.
Abstract
BACKGROUND: A major, life-limiting feature of Marfan syndrome (MFS) is the presence of aneurysmal disease. Cardiovascular intervention has dramatically improved the life expectancy of Marfan patients. Traditionally, the management of aortic root disease has been undertaken with composite-valve graft replacing the aortic valve and proximal aorta; more recently, valve sparing procedures have been developed to avoid the need for anticoagulation. This meta-analysis assesses the important surgical outcomes of the two surgical techniques. METHODS: A systematic review and meta-analysis of 23 studies reporting the outcomes of aortic root surgery in Marfan patients with data extracted for outcomes of early and late mortality, thromboembolic events, late bleeding complications and surgical reintervention rates. RESULTS: The outcomes of 2,976 Marfan patients undergoing aortic root surgery were analysed, 1,624 patients were treated with composite valve graft (CVG) and 1,352 patients were treated with valve sparing root replacement (VSRR). When compared against CVG, VSRR was associated with reduced risk of thromboembolism (OR =0.32; 95% CI, 0.16-0.62, P=0.0008), late hemorrhagic complications (OR =0.18; 95% CI, 0.07-0.45; P=0.0003) and endocarditis (OR =0.27; 95% CI, 0.10-0.68; P=0.006). Importantly there was no significant difference in reintervention rates between VSRR and CVG (OR =0.89; 95% CI, 0.35-2.24; P=0.80). CONCLUSIONS: There is an increasing body of evidence that VSRR can be reliably performed in Marfan patients, resulting in a durable repair with no increased risk of re-operation compared to CVG, thus avoiding the need for systemic anticoagulation in selected patients.
BACKGROUND: A major, life-limiting feature of Marfan syndrome (MFS) is the presence of aneurysmal disease. Cardiovascular intervention has dramatically improved the life expectancy of Marfan patients. Traditionally, the management of aortic root disease has been undertaken with composite-valve graft replacing the aortic valve and proximal aorta; more recently, valve sparing procedures have been developed to avoid the need for anticoagulation. This meta-analysis assesses the important surgical outcomes of the two surgical techniques. METHODS: A systematic review and meta-analysis of 23 studies reporting the outcomes of aortic root surgery in Marfan patients with data extracted for outcomes of early and late mortality, thromboembolic events, late bleeding complications and surgical reintervention rates. RESULTS: The outcomes of 2,976 Marfan patients undergoing aortic root surgery were analysed, 1,624 patients were treated with composite valve graft (CVG) and 1,352 patients were treated with valve sparing root replacement (VSRR). When compared against CVG, VSRR was associated with reduced risk of thromboembolism (OR =0.32; 95% CI, 0.16-0.62, P=0.0008), late hemorrhagic complications (OR =0.18; 95% CI, 0.07-0.45; P=0.0003) and endocarditis (OR =0.27; 95% CI, 0.10-0.68; P=0.006). Importantly there was no significant difference in reintervention rates between VSRR and CVG (OR =0.89; 95% CI, 0.35-2.24; P=0.80). CONCLUSIONS: There is an increasing body of evidence that VSRR can be reliably performed in Marfan patients, resulting in a durable repair with no increased risk of re-operation compared to CVG, thus avoiding the need for systemic anticoagulation in selected patients.
Entities:
Keywords:
Bentall; David procedure; Marfan syndrome (MFS); composite valve graft (CVG); total root replacement; valve sparing root
Authors: Kenton J Zehr; Alireza Matloobi; Heidi M Connolly; Thomas A Orszulak; Francisco J Puga; Hartzell V Schaff Journal: J Heart Valve Dis Date: 2005-01
Authors: Irina V Volguina; D Craig Miller; Scott A LeMaire; Laura C Palmero; Xing Li Wang; Heidi M Connolly; Thoralf M Sundt; Joseph E Bavaria; Harry C Dietz; Dianna M Milewicz; Joseph S Coselli Journal: J Thorac Cardiovasc Surg Date: 2009-05 Impact factor: 5.209
Authors: Joseph S Coselli; Irina V Volguina; Scott A LeMaire; Thoralf M Sundt; Heidi M Connolly; Elizabeth H Stephens; Hartzell V Schaff; Dianna M Milewicz; Luca A Vricella; Harry C Dietz; Charles G Minard; D Craig Miller Journal: J Thorac Cardiovasc Surg Date: 2014-02-08 Impact factor: 5.209
Authors: Raimund Erbel; Victor Aboyans; Catherine Boileau; Eduardo Bossone; Roberto Di Bartolomeo; Holger Eggebrecht; Arturo Evangelista; Volkmar Falk; Herbert Frank; Oliver Gaemperli; Martin Grabenwöger; Axel Haverich; Bernard Iung; Athanasios John Manolis; Folkert Meijboom; Christoph A Nienaber; Marco Roffi; Hervé Rousseau; Udo Sechtem; Per Anton Sirnes; Regula S von Allmen; Christiaan J M Vrints Journal: Eur Heart J Date: 2014-08-29 Impact factor: 29.983
Authors: Joel Price; J Trent Magruder; Allen Young; Joshua C Grimm; Nishant D Patel; Diane Alejo; Harry C Dietz; Luca A Vricella; Duke E Cameron Journal: J Thorac Cardiovasc Surg Date: 2015-10-27 Impact factor: 5.209
Authors: Davut Cekmecelioglu; Ourania Preventza; Kathryn G Dougherty; Subhasis Chatterjee; Susan Y Green; Guilherme V Silva; Jose G Díez; Joseph S Coselli Journal: Ann Cardiothorac Surg Date: 2021-09